CAMBRIDGE, Mass.--(BUSINESS WIRE)--Curis, Inc. (NASDAQ:CRIS), a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, today reported its financial results for the third quarter ended September 30, 2006.
